{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:45:28Z","timestamp":1785746728043,"version":"3.56.0"},"reference-count":26,"publisher":"Akademiai Kiado Zrt.","issue":"31","content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2026,8,2]]},"abstract":"<jats:p>Az egy\u00e9b, fokozott izomspasmussal j\u00e1r\u00f3 k\u00f3rk\u00e9pek mellett a der\u00e9kf\u00e1jdalomban\n                    szenved\u0151 betegek jelent\u0151s r\u00e9sz\u00e9nek enyh\u00fcl\u00e9st hoznak a centr\u00e1lisan hat\u00f3\n                    izomrelax\u00e1nsok (guaifenezin, tolperizon, metokarbamol, kl\u00f3rzoxazon, diazep\u00e1m,\n                    baklofen \u00e9s tizanidin). Ezek k\u00f6z\u00fcl az ut\u00f3bbi id\u0151ben a tolperizon hat\u00f3s\u00e1gi d\u00f6nt\u00e9s\n                    k\u00f6vetkezt\u00e9ben visszaszorult, mivel alkalmaz\u00e1sa sor\u00e1n nagy ar\u00e1nyban tapasztaltak\n                    anafilaxi\u00e1s reakci\u00f3kat. K\u00f6zlem\u00e9ny\u00fcnk c\u00e9lja a fenti gy\u00f3gyszercsoport\n                    mell\u00e9khat\u00e1sai gyakoris\u00e1g\u00e1nak elemz\u00e9se, hogy ennek bemutat\u00e1s\u00e1val seg\u00edts\u00fck a\n                    klinikusokat a megfelel\u0151 gy\u00f3gyszerv\u00e1laszt\u00e1sban. Az Eg\u00e9szs\u00e9g\u00fcgyi Vil\u00e1gszervezet\n                    adatai szerint az eml\u00edtett s\u00falyos allergi\u00e1s mell\u00e9khat\u00e1st lesz\u00e1m\u00edtva a tolperizon\n                    biztons\u00e1gos szernek sz\u00e1m\u00edt. A gy\u00f3gyszerhez kapcsolhat\u00f3 hal\u00e1loz\u00e1s (az\n                    \u00f6ngyilkoss\u00e1got is bele\u00e9rtve) a jelentett mell\u00e9khat\u00e1sok k\u00f6z\u00f6tt a diazep\u00e1m\n                    eset\u00e9ben a legnagyobb ar\u00e1ny\u00fa, amit a tizanidin \u00e9s a metokarbamol k\u00f6vet.\n                    Hat\u00e1stalans\u00e1gr\u00f3l a leggyakrabban a guaifenezin eset\u00e9ben sz\u00e1moltak be, ezt a\n                    baklofen \u00e9s a tizanidin k\u00f6veti. A hal\u00e1loz\u00e1s \u00e9s a hat\u00e1stalans\u00e1g tekintet\u00e9ben is a\n                    tolperizon volt a legkedvez\u0151bb szer. R\u00e9szletesen bemutatjuk a szerek szed\u00e9s\u00e9t\n                    megnehez\u00edt\u0151, egyes esetekben ellehetetlen\u00edt\u0151 gastrointestinalis, major\n                    neurol\u00f3giai \u00e9s pszichi\u00e1triai mell\u00e9khat\u00e1sait, valamint megeml\u00edtj\u00fck a zavar\u00f3 b\u0151r-\n                    \u00e9s szem\u00e9szeti t\u00fcneteket is. Orv Hetil. 2026; 167(31): 1224\u20131230.<\/jats:p>","DOI":"10.1556\/650.2026.33617","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T06:51:35Z","timestamp":1785739895000},"page":"1224-1230","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["A centr\u00e1lis izomrelax\u00e1ns hat\u00e1ssal rendelkez\u0151 vegy\u00fcletek mell\u00e9khat\u00e1sprofiljainak \u00f6sszehasonl\u00edt\u00e1sa"],"prefix":"10.1556","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-7294","authenticated-orcid":true,"given":"Csaba","family":"Kopitk\u00f3","sequence":"first","affiliation":[{"name":"Uzsoki Utcai K\u00f3rh\u00e1z, K\u00f6zponti Aneszteziol\u00f3giai \u00e9s Intenz\u00edv Ter\u00e1pi\u00e1s Oszt\u00e1ly Budapest, Uzsoki u. 29\u201341., 1145 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9va","family":"Pettendi","sequence":"additional","affiliation":[{"name":"G\u00f6d\u00f6ll\u0151i Semmelweis Eg\u00e9szs\u00e9gk\u00f6zpont, Neurol\u00f3giai Szakrendel\u00e9s G\u00f6d\u00f6ll\u0151 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Manca A, Cugusi L, van Tulder M, et al. Oral non-benzodiazepine\n                    muscle-relaxants for people with acute and chronic primary low back pain: a\n                    systematic review with meta-analysis. Eur Spine J. 2025; 34: 2347-2366.\n                        https:\/\/doi.org\/10.1007\/s00586-025-08786-0","DOI":"10.1007\/s00586-025-08786-0"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Nalamachu S, Pergolizzi J, Kaye R. Tolperisone for the treatment of\n                    acute muscle spasm of the back: Results from the dose-ranging phase 2 STAR study\n                    (NCT03802565). J Pain Res. 2020; 13: 3059-3069.\n                        https:\/\/doi.org\/10.2147\/JPR.S278857","DOI":"10.2147\/JPR.S278857"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Oldfield BJ, Gleeson B, Morford KL, et al. Long-term use of muscle\n                    relaxant medications for chronic pain: a systematic review. JAMA Netw Open 2024;\n                    7: e2434835.\n                    https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.34835","DOI":"10.1001\/jamanetworkopen.2024.34835"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Chou R, Peterson K, Helfand M. Comparative efficacy and safety of\n                    skeletal muscle relaxants for spasticity and musculoskeletal conditions: a\n                    systematic review. J Pain Symptom Manage 2004; 28: 140-175.\n                        https:\/\/doi.org\/10.1016\/j.jpainsymman.2004.05.002","DOI":"10.1016\/j.jpainsymman.2004.05.002"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Pangarkar SS, Kang DG, Sandbrink F, et al. VA\/DoD clinical practice\n                    guideline: diagnosis and treatment of low back pain. J Gen Intern Med. 2019; 34:\n                    2620-2629.\n                    https:\/\/doi.org\/10.1007\/s11606-019-05086-4","DOI":"10.1007\/s11606-019-05086-4"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Collaku A, Yue Y, Reed K. Efficacy and safety of guaifenesin for\n                    upper back, neck, and shoulder pain: a Phase II proof-ofconcept, multicenter,\n                    placebo-controlled, repeat-dose, parallel-group study. J Pain Res. 2017; 10:\n                    669-678. https:\/\/doi.org\/10.2147\/JPR.S126296","DOI":"10.2147\/JPR.S126296"},{"key":"R7","unstructured":"National Center for Biotechnology Information. PubChem Compound\n                    Summary for CID 3516, Guaifenesin. Available from:\n                        https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Guaifenesin [accessed:\n                    June 16, 2026]."},{"key":"R8","unstructured":"Kocsis P, Tarnawa I, Kov\u00e1cs G, et al. Mydeton: a centrally acting\n                    muscle relaxant drug of Gedeon Richter ITD. [Mydeton: a Richter centr\u00e1lis\n                    t\u00e1mad\u00e1spont\u00fa izomrelax\u00e1nsa.] Acta Pharm Hung. 2002; 72: 49-61.\n                    [Hungarian]"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Tekes K. Basic aspects of the pharmacodynamics of tolperisone, a\n                    widely applicable centrally acting muscle relaxant. Open Med Chem J. 2014; 8:\n                    17-22. https:\/\/doi.org\/10.2174\/1874104501408010017","DOI":"10.2174\/1874104501408010017"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Lee HJ, Kim YH, Kim SH, et al. Smoking has significant effects on\n                    the pharmacokinetic parameters of tolperisone. Clin Ther. 2015; 37: e61.\n                        https:\/\/doi.org\/10.1016\/j.clinthera.2015.05.181","DOI":"10.1016\/j.clinthera.2015.05.181"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Rao R, Panghate A, Chandanwale A, et al. Clinical comparative study:\n                    efficacy and tolerability of tolperisone and thiocolchicoside in acute low back\n                    pain and spinal muscle spasticity. Asian Spine J. 2012; 6: 115-122.\n                        https:\/\/doi.org\/10.4184\/asj.2012.6.2.115","DOI":"10.4184\/asj.2012.6.2.115"},{"key":"R12","unstructured":"Medicines Agency. Questions and answers on the referral for\n                    Myderison. London, 2011."},{"key":"R13","unstructured":"Sibrack J, Patel P, Hammer R. Methocarbamol. (Updated: Sep 10,\n                    2024). In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL,\n                    2026. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33351427\/\n                    [accessed: 10\/01\/2026]."},{"key":"R14","unstructured":"National Center for Biotechnology Information (2026). Methocarbamol.\n                    (PubChem Compd Summ CID 4107). Available from:\n                        https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Methocarbamol\n                    [accessed: 10\/01\/2026]."},{"key":"R15","unstructured":"National Institute of Diabetes and Digestive and Kidney Disease.\n                    Chlorzoxazone. (2017 Jan 3.) In: LiverTox\u00ae: Clinical and Research Information on\n                    Drug-In duced Liver Injury. [Internet] Available from:\n                        https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548137\/ [accessed:\n                    18\/12\/2025]."},{"key":"R16","unstructured":"National Center for Biotechnology Information Chlorzoxazone.\n                    (PubChem Compd Summ CID 2733), 2026. Available from:\n                        https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/2733 [accessed:\n                    10\/01\/2026]."},{"key":"R17","unstructured":"Dhaliwal JS, Rosani A, Saadabadi A, et al. Diazepam. (Updated 2023\n                    Aug 28). In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL,\n                    2026. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537022\/\n                    [accessed: 10\/01\/2026]."},{"key":"R18","unstructured":"Ghanavatian S, Derian A. Baclofen. 2024 Aug 11. StatPearls\n                    [Internet]. StatPearls Publishing, Treasure Island, FL, 2026. Available from:\n                        https:\/\/pubmed.ncbi.nlm.nih.gov\/30252293\/ [accessed:\n                    10\/01\/2026]."},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Paul V, Righter K, Kim E, et al. Severe hyperthermia due to oral\n                    baclofen withdrawal. BMJ Case Rep. 2020; 13: e234710. Corrected and republished:\n                    Drug Ther Bull. 2021; 59: 189-191.\n                        https:\/\/doi.org\/10.1136\/dtb.2021.234710rep","DOI":"10.1136\/dtb.2021.234710rep"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Nason MW Jr., Mason P. Medullary raphe neurons facilitate brown\n                    adipose tissue activation. J Neurosci. 2006; 26: 1190-1198.\n                        https:\/\/doi.org\/10.1523\/JNEUROSCI.4707-05.2006","DOI":"10.1523\/JNEUROSCI.4707-05.2006"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Moura-Assis A, Pluci\u0144ska K, Meseguer D, et al. Identification of a\n                    thermogenic target in the dorsal raphe nucleus for weight management in mice.\n                    Nat Commun. 2026; 17: 1295.\n                        https:\/\/doi.org\/10.1038\/s41467-025-68056-x","DOI":"10.1038\/s41467-025-68056-x"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Lee HC, Kim JM, Lim JK, et al. Central hyperthermia treated with\n                    baclofen for patient with pontine hemorrhage. Ann Rehabil Med. 2014; 38:\n                    269-272. https:\/\/doi.org\/10.5535\/arm.2014.38.2.269","DOI":"10.5535\/arm.2014.38.2.269"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Goyal L, Mallick D, Zapata MR, et al. Tizanidine toxicity from\n                    ciprofloxacin: a cautionary tale. Cureus 2022; 14: e32492.\n                        https:\/\/doi.org\/10.7759\/cureus.32492","DOI":"10.7759\/cureus.32492"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Lakatos PP, Ign\u00e1th Z, Csern\u00e1k O, et al. Separation of tolperisone\n                    and its degradation products by a dual cyclodextrin capillary electrophoresis\n                    system to study their potential role in allergic events. J Pharm Biomed Anal.\n                    2025; 252: 116532.\n                    https:\/\/doi.org\/10.1016\/j.jpba.2024.116532","DOI":"10.1016\/j.jpba.2024.116532"},{"key":"R25","unstructured":"World Health Organization. VigiAccess. Available from:\n                        https:\/\/www.vigiaccess.org\/ [accessed:\n                    18\/12\/2025]."},{"key":"R26","unstructured":"PHARMINDEX. Available from:\n                        https:\/\/www.pharmindex-online.hu\/ [accessed:\n                    18\/12\/2025]."}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/31\/article-p1224.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/31\/article-p1224.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/31\/article-p1224.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:57:40Z","timestamp":1785743860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/31\/article-p1224.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,2]]},"references-count":26,"journal-issue":{"issue":"31"},"URL":"https:\/\/doi.org\/10.1556\/650.2026.33617","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,2]]}}}